Black Diamond Therapeutic Bolsa (NASDAQ: BDTX)

Últimas noticias sobre Black Diamond Therapeutic (NASDAQ:BDTX) Bolsa

BLACK DIAMOND THERAPEUTICS I

Black Diamond Therapeutic

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

ATPC

BDTX

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

TRAW

VMAR

Sage Therapeutics sube 34% tras oferta de Biogen. Conoce los mayores ganadores y perdedores del premercado de EE.UU.

Las acciones de Sage Therapeutics (SAGE) se disparan un 34%; 20 acciones que se mueven en premercado

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutics Inc

For FY25, VEON is guiding for underlying local currency growth for total revenue of 12% - 14% YoY, and underlying EBITDA growth of 13% - 15% YoY. VEON's outlook for the Group's capex intensity is in the range of 17%-19% for 2025.

Earnings

Guidance

VEON

VEON For 2025 Expects Underlying Local Currency Revenue YoY Growth Of 12%–14%, EBITDA Growth Of 13%–15%, And Capex Intensity Of 17%–19%

Buybacks

VEON Launches Second Phase Of Share Buyback Program With Up To $35M In ADS Repurchases

VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) reported quarterly sales of $998.00 million which beat the analyst consensus estimate of $997.00 million by 0.10 percent. This is a 4.72 percent increase over sales of $953.00 million the same period last year.

Earnings Beats

VEON Q4 Sales $998.00M Beat $997.00M Estimate, EBITDA $408M Up From $367M YoY

Financial Outlook&nbsp;
The Company provides the following guidance on its future results:&nbsp;
• Product sales expected to grow to €170-180 million in 2025, driving positive cash-flows for the overall commercial business&nbsp;
• Total revenues expected to reach €180-190 million in 2025&nbsp;
• Total R&amp;D investments expected between €90 - €100 million in 2025, which will be partially offset by grant fundings and anticipated R&amp;D tax credits&nbsp;
• Continued stringent focus on cash management supporting sufficient cash runway to reach key inflection points; targeting more than 50% lower operating cash burn in 2025

VALN

Pharming For 2025 Expects Product Sales Of €170M–180M And Total Revenues Of €180M–190M; Sees R&D Investments Of €90M–100M

Valneva FY Sales €169.60M Up From €153.7M YoY, Net Loss €12.2M Compared To Net Loss €101.4M YoY

<ul>
<li>Multi-center clinical trial includes sites located in the US, UK and EU</li>
<li>Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs)</li>
<li>CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million</li>
</ul>

PHAR

Pharming Doses First Patient In Phase II Trial of Leniolisib For CVID With Immune Dysregulation

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has reportedly encountered a $1.4 billion gap between its capital expenditure and the valuation of related assets over the last six months of 2024.
What Happened: This discrepancy, highlighted in a <a href="https://www.ft.com/content/62df8d8d-31f2-445e-bfa2-c171ac43db6e">report</a> by Financial Times, comes as Tesla&#8217;s stock market valuation has plummeted from $1.7 trillion to under $800 billion.
According to the report, Tesla&#8217;s cash flow statement reveals $6.3 billion spent on property and equipment purchases in the third and fourth quarters of 2024. However, the balance sheet shows only a $4.9 billion increase in the gross value of property, plant, and equipment during the same period.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
See Also:<a href="https://www.benzinga.com/25/03/44394560/elon-musks-tesla-targeted-with-arson-attacks-in-las-vegas-kansas-city-report"> Elon Musk&#8217;s Tesla Targeted With Arson Attacks In Las Vegas, Kansas City: Report</a>
Despite Tesla&#8217;s substantial cash reserves of $37 billion, the company raised $6 billion in new debt last year.
This raises questions about Tesla&#8217;s financial strategies, especially as it plans to invest heavily in AI infrastructure, robots, computing, and batteries, with at least $11 billion earmarked for each of the coming years.
Financial experts, including Jacek Welc from SRH Berlin University, suggest that such financial anomalies could indicate weak internal controls or aggressive expense classification.
Tesla&#8217;s ongoing capital raising, despite significant cash flow, is seen as a potential red flag for accounting misstatements.
Why It Matters: The financial discrepancy at Tesla comes amid a turbulent period for Elon Musk, the company&#8217;s CEO. Musk has been juggling his responsibilities between Tesla and his role in the Department of Government Efficiency (DOGE) under the Trump administration.
In a <a href="https://www.benzinga.com/markets/25/03/44242181/elon-musk-admits-juggling-between-tesla-doge-is-difficult-says-running-businesses-with-great-difficulty-as-tsla-stock-plunges-50-in-3-months">recent interview</a>, Musk admitted to facing significant challenges in managing his businesses, coinciding with a sharp decline in Tesla&#8217;s stock.
Investors have expressed frustration over Musk&#8217;s divided focus, with some, like <a href="https://benzinga.com/markets/25/03/44346423/teslas-biggest-bull-frustrated-with-elon-musks-focus-on-doge-over-company-patience-wearing-thin">Tesla's biggest bull</a>, voicing concerns about his attention being diverted from the company. <a href="https://benzinga.com/markets/equities/25/03/44268904/elon-musks-current-leadership-situation-is-not-sustainable-for-shareholders-says-tesla-bull-needs-to-strike-a-balance-with-doge">Dan Ives</a> from Wedbush Securities has also highlighted the unsustainable nature of Musk&#8217;s current leadership situation for Tesla&#8217;s shareholders.
Tesla holds a momentum rating of 81.80% and a growth rating of 55.07%, according to <a href="https://www.benzinga.com/report/TSLA">Benzinga's Proprietary Edge Rankings</a>. The Benzinga Growth metric evaluates a stock&#8217;s historical earnings and revenue expansion across multiple timeframes, prioritizing both long-term trends and recent performance. For an in-depth report on more stocks and insights into growth opportunities, <a href="https://www.benzinga.com/screener/top-momentum-stocks">sign</a> <a href="https://www.benzinga.com/screener/top-momentum-stocks">up for Benzinga Edge.</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="837" height="145" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20023716/Tesla-Edge.jpg" alt="" class="wp-image-832903" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20023716/Tesla-Edge.jpg 837w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20023716/Tesla-Edge-300x52.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20023716/Tesla-Edge-768x133.jpg 768w" sizes="(max-width: 837px) 100vw, 837px" /></figure>
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44392619/elon-musks-tesla-secures-first-approval-towards-rolling-out-robotaxi-in-california">Elon Musk&#8217;s Tesla Secures First Approval Towards Rolling Out Robotaxi In California</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

Tech

TSLA

Elon Musk's Tesla Faces $1.4 Billion Discrepancy In Capital Expenditure: Report

Gold prices hit an all-time high Wednesday as the Federal Reserve projected slower economic growth and higher inflation, boosting demand for the safe haven.
What happened: Spot gold hit $3,056 per ounce earlier in the day before retracing slightly. Gold futures on the Commodity Exchange jumped to $3,060.20.
The yellow metal has been smashing records this year, precipitated by a dampening risk sentiment due to President Donald Trump's <a href="https://in.benzinga.com/analyst-ratings/analyst-color/25/03/44378155/exclusive-trumps-200-tariff-threat-could-price-european-alcohol-out-of-us-markets">aggressive tariff policies</a>. Spot gold has gained over 16.21% year-to-date.
On Wednesday, the central bank kept the interest rates changed, and <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44406928/economists-react-to-powell-we-are-now-seeing-the-stag-and-the-flation">lowered 2025 GDP growth projections</a> from 2.1% to 1.7%, fueling further gains for gold.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44390616/cathie-wood-believes-most-memecoins-wont-face-fearsome-declines-end-up-becoming-collectors-items">Cathie Wood Believes Most Memecoins Will Face &#8216;Fearsome Declines,&#8217; But They Could End Up Becoming Collector&#8217;s Items</a>
The rise has trickled down to physical gold-backed cryptocurrencies as well. Tether Gold and PAX Gold have gained 16.67% and 16.42% year-to-date.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 1:44 a.m. ET)</td>
</tr>
<tr>
<td>PAX Gold (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/paxg/usd">PAXG</a>)</td>
<td>+16.67%</td>
<td>$3,065.24</td>
</tr>
<tr>
<td>Tether Gold (CRYPTO: XAUt)</td>
<td>+16.42%</td>
<td>$3,052.71</td>
</tr>
</tbody>
</table>
</figure>
These increases contrasted sharply with the performance of the rest of the cryptocurrency market.&nbsp;
The overall market capitalization has shrunk 14% from $3.6 trillion to $2.8 trillion since the year began, with market barometer Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) slipping over 8%. Notably, Bitcoin has been aggressively promoted as a &#8220;digital gold&#8221; asset by its supporters.
Price Action: At the time of writing, Spot Gold was exchanging hands at 3,046.14, down 0.10% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Photo courtesy: Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363871/peter-schiff-slams-bitcoin-etfs-calls-selling-gold-for-btc-worst-timed-trade-in-history">Peter Schiff Slams Bitcoin ETFs, Calls Selling Gold For BTC &#8216;Worst-Timed Trade In History&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$PAXG

Bitcoin's Recent Struggles Aside, Gold Hit A New All-Time High Shining A Bright Spotlight On These Precious Metal Cryptos That Rocked In 2025

Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
<ul>
<li>Dren Bio deep B-cell depleter program has the potential to reset the immune system</li>
<li>Acquisition underpins path for Sanofi becoming leading immunology company</li>
<li>Sanofi to pay $600 million up front</li>
</ul>

Sanofi To Acquire Dren Bio's DR-0201 For $600M Upfront, With Up To $1.3B In Milestone Payments

<ul>
<li>Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market</li>
<li>Acquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies</li>
<li>Total transaction value of up to ~$330 million</li>
<li>Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025</li>
</ul>

OPTN

Reported Earlier, Paratek Pharmaceuticals To Acquire Optinose In Deal Worth Up To $330M, Including $9 Cash And Potential $5/Share In Future Milestones

Senior economist Mohamed El-Erian has criticized Federal Reserve Chair Jerome Powell&#8217;s use of the word &#8220;transitory&#8221; to describe the potential inflationary impact of tariffs.
What Happened: The Federal Reserve <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44405112/tariff-inflation-may-be-transitory-powell-says-stocks-rally-bitcoin-clears-85000-as-bulls-return">held rates steady</a> in the range of 4.25%-4.5% on Wednesday. Despite maintaining their median forecast of two rate cuts for the year, the Fed&#8217;s &#8216;dot plot&#8217; projections revealed a subtle shift toward one cut, though not quite definitively.
Powell revived the term &#8216;transitory&#8217; when discussing inflation. Additionally, the Fed announced a slowdown in their balance sheet reduction, decreasing quantitative tightening from $25 billion to $5 billion starting in April. However, he admitted it is "very challenging" to isolate tariff-driven inflation from broader price pressures.
El-Erian, the chief economic advisor at Allianz and former CEO and CIO of PIMCO expressed disappointment in the Fed&#8217;s language following its press conference on Wednesday.
He highlighted the Fed&#8217;s previous use of &#8220;transitory&#8221; to describe inflation in the early 2020s, a prediction that proved to be significantly wrong. This previous misjudgment led to the Fed being behind the curve on raising interest rates to combat inflation.
&#8220;I would have thought that, particularly after the big policy mistake of earlier this decade and given all the current uncertainties, some Fed officials would show greater humility,&#8221; said El-Erian.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The word — "transitory" — is back at the Federal Reserve as Chair Powell characterizes the price effects of tariffs as a one-off. I would have thought that, particularly after the big policy mistake of earlier this decade and given all the current uncertainties, some Fed…
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1902435256927388049?ref_src=twsrc%5Etfw">March 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/25/03/44354638/mark-cuban-advises-genz-to-spend-every-waking-minute-learning-about-ai-heres-a-list-of-ai-investment-opportunities-for-long-term" target="_blank" rel="noreferrer noopener">Mark Cuban Advises GenZ To ‘Spend Every Waking Minute Learning About AI:' Here's A List Of AI Investment Opportunities For Long Term</a>
Why It Matters: As tariffs imposed by President Donald Trump increased the risk of inflation in the economy, El-Erian argued that it was too early to say with any degree of confidence that the inflationary effects of tariffs would be transitory.
He also emphasized that businesses and consumers still remember the recent period of &#8220;high unanticipated inflation,&#8221; which could influence their expectations and behavior, potentially leading to persistent inflation.
The University of Michigan Consumer Sentiment Index pointed to a significant surge in inflation expectations, fueled by concerns over impending tariffs. However, Powell dismissed it, characterizing them as an &#8216;outlier&#8217; when compared to other indicators of long-term inflation expectations.
Price Action: The use of the term &#8220;transitory&#8221; pushed the stocks higher on Wednesday, while Powell said policymakers can "wait for clarity" before making moves.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose on Wednesday. The SPY advanced 1.09% to $567.13, and the QQQ also jumped 1.34% to $480.89, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Thursday, the future of Dow Jones rose by 0.30%, whereas the S&amp;P 500 and Nasdaq 100 advanced by 0.46% and 0.63% respectively.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44397069/super-micro-ai-servers-get-nvidia-boost-but-smci-plunges-25-since-delayed-10k-filing-valuation-tumbles-80-in-three-weeks">Super Micro AI Servers Get Nvidia Boost, But SMCI Plunges 25% After Delayed Filing: Valuation Tumbles 80% In 3 Weeks</a></li>
</ul>
Photo courtesy: Federal Reserve

Analyst Color

Government

Economics

Federal Reserve

Federal Reserve Brings Back 'Transitory' Inflation Amid Tariff War: Economist Mohamed El-Erian Calls It A 'Big Policy Mistake'

SWK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKH#NASDAQ">SWKH</a>) reported quarterly earnings of $0.54 per share. This is a 134.78 percent increase over earnings of $0.23 per share from the same period last year. The company reported $12.36 million in sales this quarter. This is a 24.99 percent increase over sales of $9.89 million the same period last year.

SWKH

SWK Holdings Q4 2024 GAAP EPS $0.54 Up From $0.23 YoY, Sales $12.36M Up From $9.89M YoY

MARC ROSSITER STEPS DOWN AS PRESIDENT, CEO, AND DIRECTOR
PREET DHINDSA NAMED INTERIM CEO
REAFFIRMS 2025 OUTLOOK AND CONCURRENTLY ANNOUNCES EXPANSION OF DIRECT SHAREHOLDER RETURNS

EFXT

Enerflex CEO Marc Rossiter Steps Down, CFO Preet Dhindsa Appointed Interim CEO; Reiterates 2025 Guidance

The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on March 21, 2025, subject to the satisfaction of customary closing conditions

AKBA

Reported Earlier, Akebia Therapeutics Prices $50M Public Offering Of 25M Common Shares At $2/Share

Business Outlook
For the first quarter of 2025, the Company expects net revenues to be between US$482 million and US$490 million. This forecast reflects the Company's current and preliminary views on the market, operational conditions and business strategies, which are subject to changes, particularly as to the potential impact from increasing macroeconomic uncertainties.

JOYY Expects Q1 Net Revenues Between $482M-$490M Vs.$490.78M Consensus

JOYY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate of $1.18 by 50 percent. This is a 75.25 percent increase over earnings of $1.01 per share from the same period last year. The company reported quarterly sales of $549.45 million which missed the analyst consensus estimate of $549.46 million by 0 percent. This is a 3.58 percent decrease over sales of $569.84 million the same period last year.

Earnings Misses

JOYY Q4 2024 Adj EPS $1.77 Beats $1.18 Estimate, Sales $549.45M Miss $549.46M Estimate

111 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YI#NASDAQ">YI</a>) reported quarterly losses of $(0.04) per share. This is a 95 percent increase over losses of $(0.80) per share from the same period last year. The company reported $527.14 million in sales this quarter. This is a 8.91 percent decrease over sales of $578.69 million the same period last year.

111 Q4 EPS $(0.04) Up From $(0.80) YoY, Sales $527.14M Down From $578.69M YoY

Bitwise&nbsp;Chief Investment Officer&nbsp;Matt Hougan explained Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) often contradictory behavior during market crises, despite its narrative as an inflation hedge.
What Happened: In a research note <a href="https://experts.bitwiseinvestments.com/cio-memos/dip-then-rip">released </a>Tuesday, Hougan said that short-term price dips that Bitcoin experiences during economic turbulence are due to increased market uncertainty. This uncertainty amplifies the perceived riskiness of the asset, leading to a temporary decrease in the asset&#8217;s value, also known as a &#8220;discount factor.&#8221;
Hougan used the example of tariff concerns, which have <a href="https://in.benzinga.com/trading-ideas/movers/25/03/44099481/bitcoin-ethereum-dogecoin-nosedive-as-trumps-tariff-moves-wipe-out-crypto-reserve-fueled-gains-analyst-says-breaking-through-this-barrier-will-help-btc-touch-new-highs-2">battered the apex cryptocurrency</a> over the past month. While tariffs increase the riskiness in the short term, they increase the long-term price target owing to economic disorder. 
&#8220;So even though we're more bullish than ever on Bitcoin, our short-term price target falls. That explains the pullback. But if the market stabilizes and it turns out the world's not ending and the discount factor goes back from 85% to 75%, Bitcoin will recover from the pullback,&#8221; Hougan said, describing it as a &#8220;Dip Then Rip&#8221; phenomenon.
Hougan said Bitwise remained optimistic about Bitcoin, reiterating the $1 million price target by 2029 he gave in December 2024.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44390616/cathie-wood-believes-most-memecoins-wont-face-fearsome-declines-end-up-becoming-collectors-items">Cathie Wood Believes Most Memecoins Will Face &#8216;Fearsome Declines,&#8217; But They Could End Up Becoming Collector&#8217;s Items</a>
Why It Matters: Bitcoin&#8217;s performance during market crises has been a topic of discussion among industry experts.&nbsp; Robbie Mitchnick, BlackRock&#8217;s Digital Assets head, stated Wednesday that a <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44395095/recession-would-be-a-big-catalyst-for-bitcoin-blackrocks-head-of-digital-assets-says">potential U.S. recession</a> could catalyze Bitcoin&#8217;s next bull cycle.
Meanwhile,&nbsp;Hougan said in a separate interview that <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44397546/bitcoin-could-reach-200000-in-2025-if-fed-relaxes-policy-bitwises-matt-hougan-says">Bitcoin could reach $200,000</a> by the end of 2025, if the Federal Reserve takes steps to stimulate the economy.
Price Action: At the time of writing, Bitcoin was exchanging hands at $85,876.49, up 3.42% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Year-to-date, the coin has dipped 9%.
Image via Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363871/peter-schiff-slams-bitcoin-etfs-calls-selling-gold-for-btc-worst-timed-trade-in-history">Peter Schiff Slams Bitcoin ETFs, Calls Selling Gold For BTC &#8216;Worst-Timed Trade In History&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>

Bitcoin's Crisis Paradox Decoded: Bitwise CIO Explains 'Dip Then Rip' Phenomenon

Year-to-date, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares have tumbled despite bullish analyst calls and a packed GTC keynote. On Wednesday, one wealth manager warned the AI trade is overcrowded and ripe for a pullback.
What Happened: On the day when Nvidia and other chip stocks declined, Michael Landsberg, chief investment officer at Landsberg Bennett Private Wealth Management, offered a contrarian view on AI-driven tech stocks.
"I wouldn't buy tech here on the dip," Landsberg told Reuters' Lisa Bernhard, following Nvidia's GTC 2025 keynote. "We're in a trend now where the economy is slowing a bit, there's concern about tariffs, and bluntly, everybody and their brother owns these names. So what&#8217;s happened is there&#8217;s an overexposure to them."
While analysts remain bullish on Nvidia's long-term prospects—citing a robust product roadmap, AI leadership, and strong demand—Landsberg believes the short-term picture tells a different story.&nbsp;
He added that Nvidia CEO Jensen Huang can't simply wave his hand and just kind of get the stock to move higher, noting that macroeconomic pressures and saturation in AI-related holdings are weighing on sentiment.
See Also: <a href="https://www.benzinga.com/tech/25/03/44409577/nvidia-ceo-jensen-huang-shuts-down-rumors-of-intel-foundry-takeover-nobodys-invited-us-to-a-consortium">Nvidia CEO Jensen Huang Shuts Down Rumors Of Intel Foundry Takeover: &#8216;Nobody&#8217;s Invited Us To A Consortium&#8217;</a>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Market Talk: &#039;I wouldn&#039;t buy tech on the dip,&#039; as Nvidia shares fall &#x7C; REUTERS" width="500" height="281" src="https://www.youtube.com/embed/c_ED-bbignI?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Why It's Important: Landsberg's comments highlight <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40597015/will-nvidia-continue-to-deliver-investors-sweat-over-hyped-up-expectations-and-pote">growing caution around</a> the AI trade, despite Nvidia&#8217;s roadmap extending through 2028 and analysts projecting long-term growth in data center spending.&nbsp;
"There's not really a real impetus to buy," Landsberg said, adding that when growth is slowing and tariffs are looming, there are better places to look—like Europe.
A series of announcements at the GTC AI Conference in San Jose, California did little to boost Nvidia Corp.&#8217;s stock on Tuesday, as shares fell by 3.43% during regular hours.
Since the launch of DeepSeek on Jan. 10, the chipmaker has seen its market <a href="https://in.benzinga.com/25/03/44392370/nvidia-destroys-420-billion-of-investor-wealth-since-deepseek-launch-valuation-hits-a-29-month-low-as-gtc-fails-to-ignite-stock">value shrink by $420 billion</a>.
However, JPMorgan analyst Harlan Sur believes Nvidia continues to lead in AI acceleration, staying one to <a href="https://in.benzinga.com/25/03/44396940/nvidias-ai-reign-extends-to-2028-jpmorgan-says-its-still-1-2-steps-ahead">two steps ahead of its competitors</a>.
Price Action: Despite the recent decline, Nvidia&#8217;s shares have gained 30.04% over the past 12 months. On Wednesday, the stock rose 1.81%, closing at $117.52, and continued climbing 1.08% in after-hours trading to $118.79. Year-to-date, the company&#8217;s shares are down 15.03%, according to <a href="http://pro.benzinga.com/">Benzinga Pro data</a>.
Photo Courtesy: Shutterstock.com
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42260222/how-nvidia-ceos-clever-but-nerdy-pick-up-line-turned-a-homework-proposal-into-marriage-while-building-338-trillion-ai-chip-giant-along-the-way" target="_blank" rel="noreferrer noopener">How Nvidia CEO Jensen Huang's Clever Pick-Up Line Turned A Homework Proposal Into Marriage While Building $3.38 Trillion AI Chip Giant Along The Way</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Media

NVDA

Nvidia Stock Slide Signals Time to Reposition, Says Wealth Manager Michael Landsberg: 'I Wouldn't Buy Tech Here On The Dip'

Operating Highlights for the Fourth Quarter and Full Year of 2024
<ul>
<li>Total vehicle deliveries were 79,250 units for the fourth quarter of 2024, representing a 99.8% year-over-year increase. &nbsp;</li>
<li>Total vehicle deliveries were 222,123 units in 2024, representing an 87.2% year-over-year increase.</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Deliveries</td>
<td colspan="1" rowspan="1">FY2024</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2024 Q4</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2024 Q3</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2024 Q2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2024 Q1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">222,123</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">79,250</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">55,003</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">54,811</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">33,059</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Deliveries</td>
<td colspan="1" rowspan="1">FY2023</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2023 Q4</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2023 Q3</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2023 Q2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2023 Q1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">118,685</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">39,657</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">36,395</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">27,399</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">15,234</td>
</tr>
</tbody>
</table>
</figure>

ZEEKR's Q4 Total Vehicle Deliveries Rose 99.8% Year-Over-Year To 79,250 Units, And 2024 Deliveries Climbed 87.2% To 222,123 Units

Health Care

Press Releases

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Analyst Ratings

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Comments

Black Diamond Therapeutic

Noticias

Últimas noticias sobre Black Diamond Therapeutic (NASDAQ:BDTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL